Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

Katharina Mayer, MD; Ralph Hein-Rothweiler, MD; Stefanie Schüpke, MD; Marion Janisch, MD; Isabell Bernlochner, MD; Gin Ndrepepa, MD; Dirk Sibbing, MD; Tommaso Gori, MD; Oliver Borst, MD; Stefan Holdenrieder, MD; Danny Kupka, MD; Tobias Petzold, MD; Christian Bradaric, MD; Rainer Okrojek, MD; David M. Leistner, MD; Tobias Petzold, MD; Thomas Minzel, MD; Ulf Landmesser, MD; Burkert Pieske, MD; Andreas M. Zeiher, MD; Meinrad P. Gawaz, MD; Alexander Hapfelmeier, DSc; Karl-Ludwig Laugwitz, MD; Heribert Schunkert, MD; Adnan Kastrati, MD; Steffen Massberg, MD

IMPORTANCE The assessment of new antithrombotic agents with a favorable safety profile is clinically relevant.

OBJECTIVE To test the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.

DESIGN, SETTING, AND PARTICIPANTS A phase 2 randomized clinical trial; patients were enrolled from 9 centers in Germany from November 20, 2017, to February 27, 2020; follow-up ended on March 27, 2020. The study included patients with stable ischemic heart disease (SIHD) undergoing elective percutaneous coronary intervention (PCI).

INTERVENTIONS Single intravenous infusion of revacept, 160 mg, revacept, 80 mg, or placebo prior to the start of PCI on top of standard antithrombotic therapy.

MAIN OUTCOMES AND MEASURES The primary endpoint was the composite of death or myocardial injury, defined as an increase in high-sensitivity cardiac troponin to at least 5 times the upper limit of normal within 48 hours from randomization. The safety endpoint was bleeding type 2 to 5 according to the Bleeding Academic Research Consortium criteria at 30 days.

RESULTS Of 334 participants (median age, 67.4 years; interquartile range, 60-75.1 years; 253 men [75.7%]; and 330 White participants [98.8%]), 120 were allocated to receive the 160-mg dose of revacept, 121 were allocated to receive the 80-mg dose, and 93 received placebo. The primary end point showed no significant differences between the revacept and placebo groups: 24.4%, 25.0%, and 23.3% in the revacept, 160 mg, revacept, 80 mg, and placebo groups, respectively (P = .98). The high dose of revacept was associated with a small but significant reduction of high-concentration collagen-induced platelet aggregation, with a median 26.5 AU × min (interquartile range, 0.5-62.2 AU × min) in the revacept, 160 mg, group; 43.5 AU × min (interquartile range, 22.8-99.5 AU × min) in the revacept, 80 mg, group; and 41.0 AU × min (interquartile range, 31.2-101.0 AU × min) in the placebo group (P = .02), while adenosine 5’-diphosphate–induced aggregation was not affected. Revacept did not increase Bleeding Academic Research Consortium type 2 or higher bleeding at 30 days compared with placebo: 5.0%, 5.9%, and 8.6% in the revacept, 160 mg, revacept, 80 mg, and placebo groups, respectively (P = .36).

CONCLUSIONS AND RELEVANCE Revacept did not reduce myocardial injury in patients with stable ischemic heart disease undergoing percutaneous coronary intervention. There were few bleeding events and no significant differences between treatment arms.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03312855

Published online March 31, 2021.

© 2021 American Medical Association. All rights reserved.
Patients undergoing percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) or acute coronary syndromes (ACS) receive dual antiplatelet therapy (DAPT) consisting of aspirin in combination with a P2Y12 inhibitor to prevent periprocedural and postprocedural ischemic events. Despite routine use of DAPT, patients undergoing PCI continue to experience periprocedural ischemic events, which represent strong and independent predictors for unfavorable outcome including mortality. Clopidogrel, the P2Y12 inhibitor recommended in patients with SIHD undergoing elective PCI, is limited by a delayed onset and considerable interpatient variability of its antiplatelet action. Rapidly acting antiplatelet agents that can be applied intravenously or intra-arterially are another alternative. Yet antiplatelet drugs that exert rapid and reliable antithrombotic efficacy without increasing the risk of bleeding represent an important unmet clinical need.

An optimal antithrombotic agent inhibits platelet function selectively at the site of atherosclerotic plaque injury (spontaneous or PCI-induced) without affecting systemic hemostasis. This requires targeting of thrombotic pathways that differ between healthy and atherosclerotic vasculature. Collagen fibers constitute the most thrombogenic macromolecular components of the extracellular matrix of atherosclerotic plaques. When collagen is exposed during atherosclerotic plaque rupture, it binds platelet glycoprotein VI (GPVI), the major platelet collagen receptor. Glycoprotein VI in turn mediates local platelet recruitment, activation, and aggregation. Glycoprotein VI is an attractive antiplatelet target because GPVI-mediated platelet response plays a central role during myocardial infarction and stroke but is less relevant in physiological hemostasis. We described a novel competitive antagonist to collagen-GPVI signaling named revacept (advanceCOR GmbH). Revacept is a dimeric, soluble fusion protein composed of the extracellular domain of the GPVI receptor and the human Fc-fragment. It competes with endogenous platelet GPVI for binding to exposed collagen fibers and inhibits collagen-mediated platelet adhesion and aggregation selectively at the site of plaque rupture. In addition, revacept blocks binding of von Willebrand factor to collagen and inhibits von Willebrand factor-mediated platelet activation. As a lesion-directed drug, revacept does not interfere with the function of circulating platelets beyond the atherosclerotic lesion. As a consequence, revacept inhibits atherothrombosis but has little effect on systemic hemostasis or bleeding in animal models and in a phase 1 clinical trial. However, data on the clinical efficacy and safety of revacept in patients undergoing PCI are currently lacking.

The Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovascular Revacept in Patients With Chronic Coronary Syndromes Undergoing Percutaneous Coronary Intervention (ISAR-PLASTER) trial is a randomized, double-blind phase 2 trial designed to test, for the first time to our knowledge, the efficacy and safety of 2 different doses of revacept in patients with SIHD undergoing elective PCI administered in addition to standard DAPT.

Key Points

Question Does the addition of revacept, a novel platelet glycoprotein VI antagonist, in addition to currently recommended antithrombotic therapy in the setting of percutaneous coronary intervention (PCI) in patients with stable ischemic heart disease (SIHD) have an effect on the myocardial injury rate?

Findings In this phase 2 randomized clinical trial, revacept did not reduce myocardial injury in patients with SIHD undergoing PCI. There were few bleeding events and no significant differences between treatment arms, and the 160-ng dose of revacept had a small but statistically significant effect on collagen-induced but not adenosine 5'-diphosphate-induced platelet aggregation.

Meaning In patients with SIHD undergoing PCI, addition of revacept to standard antithrombotic therapy does not reduce the incidence of myocardial injury.

Methods

Study Design

The ISAR-PLASTER was an investigator-initiated, multicenter, randomized, double-blind trial that enrolled patients with SIHD undergoing PCI at 9 participating study sites in Germany. The flow of patients in the trial is shown in Figure 1. The study had an academic sponsor (Deutsches Herzzentrum München) and was approved by the relevant ethics committee for each participating site. It was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was provided by all the patients before enrollment. An independent data safety and monitoring board oversaw the trial. An external service provider did study monitoring for all patients. The formal trial protocol can be found in Supplement 1. A detailed list of trial committee members, participating centers and investigators (eAppendix 1), the coordinating center (eAppendix 2), and statisticians (eAppendix 3) is provided in Supplement 2.

Patient Selection

Eligible patients were 18 years or older, presented with SIHD, had normal high-sensitivity cardiac troponin T (hsTnT) level, and angiographic evidence of coronary artery disease (CAD) with an indication for PCI. A comprehensive list of inclusion and exclusion criteria is provided in the eMethods in Supplement 2. Details of the trial rationale, design, and methods have been reported previously.

Study Procedures

We randomly assigned eligible patients to receive either placebo, revacept, 80 mg, or revacept, 160 mg. We selected these doses based on the phase 1 study testing different revacept doses ranging from 10 to 160 mg in healthy volunteers. In that study, inhibition of collagen-induced platelet aggregation at 2 hours after administration was greatest in the 80- and 160-mg dose groups. The mean (SD) reported plasma half-life of revacept after 80- and 160-mg doses was 137.6 (27.2) hours and 136.6 (36.7) hours, respectively. No drug-related adverse events were observed with these doses.
Randomization was performed in a double-blinded manner stratified by study center with the use of a centralized computer system, embedded in the electronic case report form. Patients received the study drug (revacept, 80 mg, revacept, 160 mg, or placebo) in the form of a single intravenous infusion as soon as possible after the decision to perform PCI had been made and prior to the start of the PCI procedure (defined as guidewire passage over the stenosis). In addition to the study drug, all patients were treated with standard periprocedural antithrombotic therapy composed of clopidogrel, aspirin, and heparin (or bivalirudin) based on local practice and current guideline recommendations on myocardial revascularization.

Outcomes and Definitions
The primary end point was a composite of death or myocardial injury, defined as the increase in hsTnT value to at least 5 times the upper limit of normal within 48 hours from randomization (eMethods in Supplement 2).

The secondary end points included peak hsTnT within 48 hours from randomization as well as all-cause mortality, myocardial infarction (defined according to the third universal definition of myocardial infarction), PCI-related (type 4a) myocardial infarction, stroke, definite stent thrombosis defined according to Academic Research Consortium (ARC) criteria, and urgent coronary revascularization within the first 30 days after randomization. Bleeding type 2 or higher according to the Bleeding Academic Research Consortium (BARC) criteria at 30 days was defined as the safety end point.

Detailed definitions of the clinical outcomes are previously published. An independent event adjudication committee (EAC) blinded to the randomly assigned treatment adjudicated all suspected clinical events.

Assessment of Platelet Function
Venous whole blood was obtained from patients using 1.6-mL hirudin tubes (Sarstedt). The blood samples were planned to be collected from patients enrolled in Deutsches Herzzentrum München (n = 168) for the assessment of both collagen-induced and adenosine 5′-diphosphate (ADP)-
induced platelet aggregation and in Klinikum rechts der Isar, Munich (n = 37), for the assessment of ADP-induced platelet aggregation.

Platelet aggregation was assessed with the Multiplate Analyzer (Roche Diagnostics) after stimulation with adenosine diphosphate (ADP-test) or with 3 different concentrations of collagen, 31 μg/mL, 93 μg/mL, and 253 μg/mL. The results of the tests were quantified as area under the curve (AUC) of aggregation units (AU): AUC = AU × min.

Statistical Analysis
Details of the sample size calculation are provided in a previous publication. The statistical analysis plan can be found in Supplement 3.

Confirmatory hypothesis testing of the primary efficacy end point was performed in a sequential order. First, significance of the treatment effect across the 3 groups was assessed by a test for trend on a 2-sided 5% significance level using a binary logistic regression model and by using the values 0, 1, and 2 to code the placebo group, the lower-dose revacept group, and the higher-dose revacept group as a continuous variable. The logistic regression model accounted for stratification by inclusion of centers as a factor variable. In case of a significant difference between the 3 groups, the 2 revacept groups were to be compared by using a χ² test on a 2-sided 20% significance level. Five missing values in the primary end point were conservatively imputed (ie, as an event in the revacept arms and as no event in the control arm) in an additional exploratory sensitivity analysis. Further exploratory analyses of secondary and safety end points were performed similar to the analysis of the primary end point using binary logistic regression models and linear regression models. Time-dependent risks until 30 days are given by Kaplan-Meier estimates as there were no competing risks. Exploratory hypothesis testing was performed at 2-sided 5% significance levels.

Three populations were used for the statistical analysis. The full-analysis set included all patients who have been randomized in concordance with the intention-to-treat principle. The modified intention-to-treat population included all patients belonging to the full analysis set who received the study medication. The per-protocol population included all patients of the full analysis set who did not show major protocol deviations. Baseline characteristics were analyzed in the full-analysis set. Confirmatory analysis of the primary end point was performed using the full analysis set (intention-to-treat population). Safety end points as well as laboratory and electrocardiogram (ECG) parameters at 48 hours after randomization were analyzed using the modified intention-to-treat population. The per-protocol population was used for additional exploratory analyses.

Descriptive statistics for quantitative data are median and interquartile range (IQR). Qualitative data are presented by absolute and relative frequencies. Exploratory hypothesis testing of group differences in baseline characteristics, as well as in laboratory and ECG parameters at 48 hours after randomization, was performed by Kruskal-Wallis rank sum tests and χ² tests.

Sample Size Calculation
We planned to test for 2 ordered hypotheses. First, we planned to test for a significant difference in the primary end point among the 3 study groups in favor of revacept treatment. Sample size calculation was based on the following assumptions: incidence of the primary end point of 25% in the placebo group (as shown by an analysis of 2000 patients meeting study criteria from the database of the Deutsches Herzzentrum München) and 8% and 17% in the higher 160-mg and lower 80-mg revacept dose groups, respectively. Our assumptions were based on large reductions in the primary end point by revacept because myocardial injury as defined in this trial is a very soft end point and only large reductions in its incidence might be expected to have a measurable effect on hard events in a future trial sufficiently powered for clinical end points. Hence, this trial was only powered to see a very large treatment effect because such a large reduction in myocardial injury would likely translate into a clinically meaningful benefit. Use of a 2-sided α level of 0.05 and a power of 80% leads to a total sample size of 270 patients (90 patients in each of the 3 study groups). Second, in the case of a statistically significant difference between the 3 study groups, we planned to test for a difference in the 2 revacept dose groups. Instead of considering a dose with the larger response rate, we preferred to increase the type I error rate at α = 0.20.

References in support of this method are given in the previous publication of trial design. Detection of a difference between 8% and 17% with a power of 80% using a type I error rate of 20% required 121 patients in each of the 2 revacept treatment arms for a total of 242 patients. The sample size of 90 patients in the placebo group was added to the 242 patients in the 2 revacept groups to form the total sample size of 332 patients for this trial.

Results

Study Population
Between November 20, 2017, and February 27, 2020, we screened 509 patients who had signed the informed consent as possible candidates for participation in the study. Figure 1 reports the reasons why 175 patients were not randomized. Thus, 334 patients were successfully randomized and constitute the intention-to-treat population (Figure 1). Baseline clinical, angiographic, and interventional characteristics are shown in Table 1 as well as in eTables 1 and 2 in Supplement 2.

Efficacy
At 48 hours, the combined primary end point occurred in 80 of 329 patients with peak hsTnT measurements (24.3%) without significant differences between the revacept and placebo groups (29 of 119 patients allocated to revacept, 160 mg [24.4%]; 30 of 120 patients allocated to revacept, 80 mg [25.0%]; and 21 of 90 patients allocated to placebo [23.3%]; P = .98 [Figure 2]). Because there was only 1 patient who died, this result practically consists of the myocardial injury component. There was no statistically significant difference in the incidence of the primary end point between patients with and...
Within 48 hours, the median peak hsTnT was 31.5 ng/L (IQR, 18.0-66.8 ng/L) and 28.0 ng/L (IQR, 16.0-65.0 ng/L) in the revacept, 80 mg and 160-mg groups, respectively, vs 32.0 ng/L (IQR, 20.8-62.3 ng/L) in the placebo group (P = .44). Only 4 patients (2 patients in the revacept, 160 mg, group and 1 in the revacept, 80 mg, and placebo groups, respectively) showed an increase in hsTnT of at least 70 times the upper limit of normal within 48 hours from randomization.

Riskestimates of the primary endpoint with imputation of the missing values in the modified intention-to-treat and in the per protocol population did not differ by more than 0.6% from the values obtained in the intention-to-treat population, confirming the robustness of the finding. These analyses also showed no significant difference between the groups (data not shown).

### Table 1. Baseline Patient Characteristics*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
<th>Revacept 160 mg (n = 120)</th>
<th>80 mg (n = 121)</th>
<th>Placebo (n = 93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR), y</td>
<td>67.3 (61.5-75.5)</td>
<td>67.4 (60.4-75.1)</td>
<td>67.8 (60.8-74.8)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>38 (31.7)</td>
<td>24 (19.8)</td>
<td>19 (20.4)</td>
<td></td>
</tr>
<tr>
<td>Weight, median (IQR), kg</td>
<td>82.0 (70.8-92.0)</td>
<td>82.0 (74.0-94.0)</td>
<td>82.0 (73.0-91.0)</td>
<td></td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>116 (96.7)</td>
<td>121 (100)</td>
<td>93 (100)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1 (0.8)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>3 (2.5)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>32 (26.7)</td>
<td>35 (28.9)</td>
<td>22 (23.7)</td>
<td></td>
</tr>
<tr>
<td>Insulin therapy, No./total No.</td>
<td>12/32 (37.5)</td>
<td>11/35 (31.4)</td>
<td>8/22 (36.4)</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>24 (20.0)</td>
<td>20 (16.5)</td>
<td>23 (24.7)</td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>160 (88.3)</td>
<td>103 (85.1)</td>
<td>87 (93.5)</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>110 (91.7)</td>
<td>108 (89.3)</td>
<td>80 (86.0)</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>21 (17.5)</td>
<td>27 (22.3)</td>
<td>26 (28.0)</td>
<td></td>
</tr>
<tr>
<td>PCI</td>
<td>60 (50.0)</td>
<td>71 (58.7)</td>
<td>57 (61.3)</td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>10 (8.3)</td>
<td>11 (9.1)</td>
<td>6 (6.5)</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>2 (1.7)</td>
<td>3 (2.5)</td>
<td>3 (3.2)</td>
<td></td>
</tr>
<tr>
<td>Peripheral arterial occlusive disease</td>
<td>11 (9.2)</td>
<td>8 (6.6)</td>
<td>7 (7.5)</td>
<td></td>
</tr>
<tr>
<td>COPD</td>
<td>8 (6.7)</td>
<td>4 (3.3)</td>
<td>5 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Kidney insufficiency</td>
<td>14 (11.7)</td>
<td>12 (9.9)</td>
<td>5 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Family history of premature CAD, No./total No. (%)b</td>
<td>53 (44.2)</td>
<td>52/119 (43.7)</td>
<td>36/92 (39.1)</td>
<td></td>
</tr>
<tr>
<td>High-sensitivity cardiac troponin T, median (IQR), ng/L</td>
<td>11.0 (8.8-13.0)</td>
<td>11.0 (8.0-13.0)</td>
<td>10.0 (7.0-13.0)</td>
<td></td>
</tr>
<tr>
<td>Creatinine, median (IQR), mg/dL</td>
<td>1.0 (0.9-1.1)</td>
<td>1.0 (0.8-1.1)</td>
<td>0.9 (0.8-1.1)</td>
<td></td>
</tr>
<tr>
<td>Body temperature, median (IQR), °Cc</td>
<td>36.5 (36.4-36.7)</td>
<td>36.5 (36.4-36.8)</td>
<td>36.6 (36.5-36.8)</td>
<td></td>
</tr>
<tr>
<td>Heart rate, median (IQR), bpm</td>
<td>64.5 (58.8-72.2)</td>
<td>66.0 (58.0-72.0)</td>
<td>66.0 (57.0-71.0)</td>
<td></td>
</tr>
<tr>
<td>Blood pressure, median (IQR), mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>145.0 (128.8-154.0)</td>
<td>137.0 (124.0-150.0)</td>
<td>141.0 (130.0-154.0)</td>
<td></td>
</tr>
<tr>
<td>Diastolic</td>
<td>80.0 (72.0-90.0)</td>
<td>78.0 (71.0-83.0)</td>
<td>80.0 (72.0-87.0)</td>
<td></td>
</tr>
<tr>
<td>Access site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral</td>
<td>57 (47.5)</td>
<td>67 (55.4)</td>
<td>40 (43.0)</td>
<td></td>
</tr>
<tr>
<td>Radial</td>
<td>62 (51.7)</td>
<td>54 (44.6)</td>
<td>52 (55.9)</td>
<td></td>
</tr>
<tr>
<td>Brachial</td>
<td>1 (0.8)</td>
<td>0</td>
<td>1 (1.1)</td>
<td></td>
</tr>
<tr>
<td>No. of diseased coronary vessels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>19 (15.8)</td>
<td>23 (19.0)</td>
<td>15 (16.1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>41 (34.2)</td>
<td>36 (29.8)</td>
<td>28 (30.1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>60 (50.0)</td>
<td>62 (51.2)</td>
<td>50 (53.8)</td>
<td></td>
</tr>
<tr>
<td>Closure device</td>
<td>39 (32.5)</td>
<td>48 (39.7)</td>
<td>26 (28.0)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CAGB, coronary-artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention.

* There were no significant between-group differences in clinical and angiographic characteristics at baseline.

** Information about family history of premature CAD not available in 3 patients (2 in the revacept, 80 mg, group and 1 in the placebo group).

---

those without clopidogrel loading prior to PCI (63 of 270 [23.3%] and 17 of 59 [28.8%], respectively; P = .37). Within 48 hours, the median peak hsTnT was 31.5 ng/L (IQR, 18.0-66.8 ng/L) and 28.0 ng/L (IQR, 16.0-65.0 ng/L) in the revacept, 80 mg and 160-mg groups, respectively, vs 32.0 ng/L (IQR, 20.8-62.3 ng/L) in the placebo group (P = .44). Only 4 patients (2 patients in the revacept, 160 mg, group and 1 in the revacept, 80 mg, and placebo groups, respectively) showed an increase in hsTnT of at least 70 times the upper limit of normal within 48 hours from randomization. Risk estimates of the primary end point with imputation of the missing values in the modified intention-to-treat and in the per protocol population did not differ by more than 0.6% from the values obtained in the intention-to-treat population, confirming the robustness of the finding. These analyses also showed no significant difference between the groups (data not shown).

The composite of all-cause death, myocardial infarction, stroke, or urgent revascularization within 30 days from randomization was observed in 9 of 334 patients (2.7%) of the entire cohort without significant difference between the groups (3 of 120 patients [2.5%] allocated to revacept, 160 mg, 4 of 121 patients [3.3%] allocated to revacept, 80 mg, and 2 of 93...
Discussion

Drugs that allow a rapid and profound platelet inhibition without increasing the risk of bleeding are conceptually appealing for periprocedural antithrombotic management in patients undergoing PCI. The ISAR-PLASTER is a phase 2 study that, for the first time to our knowledge, tests the efficacy and safety of revacept in patients with SIHD undergoing elective PCI. Revacept is a novel lesion-directed competitive inhibitor to the platelet collagen receptor GPVI that efficiently prevents arterial thrombosis, but has little effect on physiologic hemostasis in animal models and did not cause bleeding in healthy individuals in a phase I clinical trial.10,14 The trial shows that in patients with low-risk SIHD, revacept administered on top of standard DAPT did not affect the primary clinical efficacy end point, a myocardial injury surrogate. However, a high dose of revacept leads to a significant additional increase in platelet inhibition in patients treated with standard antithrombotic therapy. Despite providing a more robust platelet inhibition, the high dose of revacept on top of standard DAPT was not associated with an increase in bleeding.

The functional target of revacept is GPVI, a type I transmembrane protein expressed by megakaryocytes and platelets that belongs to the immunoglobulin superfamily. Glycoprotein VI was first described in 1982 as a protein that was missing in a patient with a severe collagen-activation defect in platelets.26 Since then, GPVI has been identified as the central collagen receptor expressed on platelets.7-8 When thrombogenic collagen fibers are exposed during atherosclerotic plaque rupture, binding of platelet GPVI to exposed collagen triggers local adhesion. This step in the platelet adhesion cascade is essential for subsequent activation and aggregation of platelets. In addition, GPVI binds to fibrin and has major roles in thrombus growth and stability.27,28 Inhibition or ablation of GPVI therefore yields strong protection against arterial thrombosis in animal models.7,9 However, despite major roles of GPVI in several critical aspects of atherothrombosis, GPVI deficiency is generally associated with minimal effects on hemostasis in animal models.29,30 This suggests that physiologic hemostasis does not require GPVI and indicates that pharmacologic GPVI modulation may provide a novel concept of antithrombotic therapies that do not increase bleeding.31

Research on new antiplatelet drugs is increasingly focusing on preserving hemostasis.32 The ISAR-PLASTER is, to our knowledge, the first phase 2 clinical trial testing the efficacy

Figure 2. Primary End Point in the 3 Treatment Groups

The primary end point was a composite of death or myocardial injury, defined as increase in high-sensitivity cardiac troponin T at least 5 times the upper limit of normal within 48 hours from randomization. There was only 1 death in the trial; thus, the end point largely reflects myocardial injury.

Safety

Figure 2. Primary End Point in the 3 Treatment Groups

The characteristic of patients with and without planned platelet function evaluation are shown in eTables 6 and 7 in Supplement 2. Revacept significantly reduced platelet aggregation in response to collagen in the 93 μg/mL (P = .03) and 253 μg/mL concentration (Figure 3A; P = .02) as compared with placebo. Enhanced platelet inhibition by revacept was specific to the collagen-GPVI axis because we did not observe significant intergroup differences in the platelet response to ADP (median, 136.0 AU, IQR, 99.0-177.0 AU in the revacept, 160 mg, group; 167.0 AU, IQR, 109.5-204.5 AU in the revacept, 80 mg, group; and 143.0 AU, IQR, 108.2-209.2 AU in the placebo group; P = .11; Figure 3B). A detailed presentation of the platelet function data is included in eTable 8 in Supplement 2.

Figure 3. Platelet Function in the 3 Treatment Groups

The incidence of the key secondary safety end point of BARC type 2 to 5 bleeding differed marginally between the groups in the modified intention-to-treat population: it was 5.0% (6 patients) in the revacept, 160 mg, group; 5.9% (7 patients) in the revacept, 80 mg, group; and 8.6% (8 patients) in the placebo group; P = .36 (eFigure in Supplement 2), with all of the events recorded during the first 2 days after randomization. Table 2 summarizes all BARC type 2 to 5 bleedings across groups and shows that most of these events were classified as less severe BARC type 2 bleeding. The BARC type 1 bleeding was observed in 15 of 120 patients (12.5%) in the revacept, 160 mg, group; 13 of 119 patients (10.9%) in the revacept, 80 mg, group; and 5 of 93 patients (5.4%) in the placebo group (P = .09).

In the modified intention-to-treat population, laboratory parameters at 48 hours were not significantly different between the groups (eTable 4 in Supplement 2). In addition, there were no significant between-group differences in ECG parameters at 48 hours, except for a slight but significant prolongation of the QTc interval in the revacept groups (median, 423 milliseconds, IQR, 404-447 milliseconds in the revacept, 160 mg, group; 421 milliseconds, IQR, 400-436 milliseconds in the revacept, 80 mg, group; and 414 milliseconds, IQR, 399-435 milliseconds in the placebo group (P = .03; eTable 5 in Supplement 2).
and safety of a pharmacologic approach targeting GPVI in patients with CAD. Different approaches to block platelet GPVI have been developed and are currently tested in preclinical models, predominantly including inhibitory monoclonal antibodies that bind to GPVI on circulating blood platelets.\textsuperscript{17,32} The results of phase 2 clinical studies with inhibitors of platelet GPVI-mediated adhesion pathways in patients with cerebrovascular disease, such as Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02) and Acute Ischemic Stroke Interventional Study (ACTIMIS), are being awaited.

Two aspects are likely to explain why enhanced platelet inhibition provided by revacept did not translate into increased clinical efficacy in the ISAR-PLASTER trial. First, the primary endpoint of our trial included the 5-time increase in hsTnT, a surrogate endpoint of myocardial injury that has little prognostic impact.\textsuperscript{33} In fact, only much higher increases in hsTnT (70 times) have been found with a significant prognostic value.\textsuperscript{34,35} The incidence of major adverse cardiovascular events at 30 days was 2.5%, indicating that low-risk patients were enrolled in the ISAR-PLASTER trial. Future studies are being planned to address whether patients at higher risk of ischemic events triggered by collagen-induced platelet activation, in particular patients with ACS, derive benefit from a 160-mg dose of revacept. Second, the surrogate of myocardial injury used in our trial is subject to triggers that may not be modifiable by revacept. As a lesion-directed drug, revacept does not interfere with the function of circulating platelets beyond the coronary lesion. Hence, key triggers of type 4a myocardial infarction, including side branch occlusion owing to plaque shifting or distal plaque material embolization, are unlikely to respond to inhibition of GPVI-collagen interaction by revacept.

**Limitations**

Our study has several limitations. First, the trial enrolled patients with SIHD undergoing elective PCI who were at very low risk of ischemic events. All patients routinely received standard antithrombotic therapy. Second, as a phase 2 trial, ISAR-PLASTER was not powered for hard clinical endpoints. The trial was only powered for detecting extremely large reductions in the primary endpoint represented by a surrogate of myocardial injury with little prognostic value.

**Conclusions**

In this first-in-class phase 2 trial on a competitive GPVI inhibitor, revacept did not reduce myocardial injury in patients with SIHD undergoing PCI. There were few bleeding events and no significant differences between treatment arms. The 160-mg dose of revacept had a small but statistically significant effect on collagen-induced but not ADP-induced platelet aggregation.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
<th>Placebo (n = 93)</th>
<th>Revacept 160 mg (n = 120)</th>
<th>Revacept 80 mg (n = 119)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARC type 2-5</td>
<td>6 (5.0)</td>
<td>7 (5.9)</td>
<td>8 (8.6)</td>
<td>.36</td>
<td></td>
</tr>
<tr>
<td>Type 2</td>
<td>5</td>
<td>5</td>
<td>7</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Type 3a</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Type 3b</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Type 3c</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Type 4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Type 5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. Safety End Point at 30 Days**

Abbreviations: BARC, Bleeding Academic Research Consortium; NA, not applicable.

**Figure 3. Inhibition of Collagen-Induced Platelet Aggregation (A) and ADP-Induced Platelet Aggregation (B)**

Horizontal bars indicate the median values, boxes indicate the 25th and 75th percentiles, and vertical lines indicate the 5th and 95th percentiles. The results are shown for collagen concentration of 253 μg/mL. ADP indicates adenosine 5’-diphosphate; AU, aggregation unit.
ARTICLE INFORMATION

Accepted for Publication: February 2, 2021.
Published Online: March 31, 2021.

Author Affiliations: Klinik für Herz- und Kreislaufforschungen, Deutsches Herzzentrum München, Technical University of Munich, Munich, Germany (Mayer, Schüpke, Janisch, Ndrepepa, Schunkert, Kastrati); Department of Cardiology, Medizinische Klinik und Poliklinik I, Munich University Clinic, Ludwig-Maximilian University of Munich, Munich, Germany (Hein-Rothweiler, Sibbing, Kupla, Petzold, Massberg); German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (Schüpke, Bernlochner, Sibbing, Laugwitz, Schunkert, Kastrati, Massberg), Medizinische Klinik und Poliklinik Innere Medizin I, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (Borxlochner, Bradaric, Okrojec, Laugwitz); Privatklinik Lauterbacher Mühle am Ostersee, Ilfeldorf, Germany (Sibbing); Department of Cardiology, University Medical Center Mainz, Mainz, Germany (Gori, Münzel); German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Germany (Gori, Münzel, Zeiher); Medizinische Klinik III-Kardiologie und Angiologie, Eberhard Karls University of Tübingen, Tübingen, Germany (Borst, Gawaz); Institut für Laboratoriumsmedizin, Deutsches Herzzentrum München, Technical University of Munich, Munich, Germany (Hollenrieder), Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Kardiologie, Berlin, Germany (Leinster, Landmesser), German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (Leinster, Tripell, Landmesser, Piecke); Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum, Department of Internal Medicine and Cardiology, German Heart Center, Berlin, Germany (Tripell, Piecke); CardioDivision, Department of Medicine III, Johann Wolfgang Goethe University, Frankfurt, Germany (Zeiher); Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich School of Medicine, Munich, Germany (Haplfeimeier), Institute of General Practice and Health Care Research, Technical University of Munich School of Medicine, Munich, Germany (Haplfeimeier).

Author Contributions: Drs Massberg and Kastrati had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Mayer and Hein-Rothweiler contributed equally to the manuscript.

Concept and design: Mayer, Schüpke, Bernlochner, Gori, Zeiher, Laugwitz, Kastrati, Massberg. Acquisition, analysis, or interpretation of data: Mayer, Hein-Rothweiler, Schüpke, Janisch, Bernlochner, Ndrepepa, Sibbing, Borx, Holdenerrieder, Kupla, Petzold, Bradaric, Okrojec, Leinster, Tripell, Muenzel, Landmesser, Piecke, Gawaz, Haplfeimeier, Schunkert, Kastrati, Massberg. Drafting of the manuscript: Mayer, Hein-Rothweiler, Gori, Kupla, Massberg.

Critical revision of the manuscript for important intellectual content: Mayer, Hein-Rothweiler, Schüpke, Janisch, Bernlochner, Ndrepepa, Sibbing, Borx, Holdenerrieder, Kupla, Petzold, Bradaric, Okrojec, Leinster, Tripell, Muenzel, Landmesser, Piecke, Zeiher, Gawaz, Haplfeimeier, Laugwitz, Schunkert, Kastrati, Massberg.


Conflict of Interest Disclosures: Dr Hein-Rothweiler reported grants from German Center for Cardiovascular Research, Deutsches Herzzentrum München, the Federal Ministry of Education and Research, and advanceCOR GmbH during the conduct of the study. Dr Schüpke reported grants from Kröner-Fresenius-Stiftung (Else Kröner-Memorial grant) and support in other studies. Drs Mayer and Kastrati had no conflicts of interest.

Conflict of Interest Disclosures: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.


REFERENCES

Efficacy and Safety of Revacept in Patients Undergoing Elective PCI for Stable Ischemic Heart Disease

Original Investigation Research


